Published May 1993 | Version v1
Journal article

Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites -current status

  • 1. Hammersmith Hospital, London (United Kingdom). M.R.C. Cyclotron Unit
  • 2. Karolinska Sjukhuset, Stockholm (Sweden)
  • 3. CEA, 91 - Orsay (France). Service Hospitalier Frederic Joliot
  • 4. CEA, CYCERON, Caen (France)
  • 5. Bristol Univ. (United Kingdom). School of Medical Sciences

Description

The status of the radiochemical development and biological evaluation of radioligands for PET studies of central benzodiazepine (BZ) receptors and the so-called peripheral benzodiazepine binding sites, here discriminated and referred to as PK binding sites, is reviewed against current pharmacological knowledge, indicating those agents with present value and those with future potential. Practical recommendations are given for the preparation of two useful radioligands for PET studies, [N-methyl-11C]flumazenil for central BZ receptors, and [N-methyl]-11C]PK 11195 for PK binding sites. Quality assurance and plasma metabolite analysis are also reviewed for these radioligands and practical recommendations are given on methodology for their performance. (author)

Additional details

Publishing Information

Journal Title
Nuclear Medicine and Biology
Journal Volume
20
Journal Issue
4
Journal Page Range
p. 503-525.
ISSN
0883-2897
CODEN
NMBIEO